Nano Lett 2005, 5:697.CrossRef 25. Choi J, Sauer G, Göring P, Nielsch K, Wehrspohn RB, Gösele U: Monodisperse metal nanowire arrays on Si by integration of template synthesis Dibutyryl-cAMP molecular weight with silicon technology . J Mater Chem 2003, 13:1100.CrossRef 26. Musselman KP, Mulhollan GJ, Robinson AP, Schmidt-Mende L, MacManus-Driscoll JL: Low-temperature synthesis of large-area, free-standing nanorod arrays on ITO/Glass and other conducting substrates . Adv Mater 2008, 20:4470–4475.CrossRef 27. Parkhutik VP, Shershulsky VI: Theoretical modelling of porous oxide growth on aluminium . J Phys D 1992, 25:1258.CrossRef 28. Guo PT, Xia ZL, Xue YY,
Huang CH, Zhao LX: Morphology and transmittance of porous alumina on glass substrate . Appl Surface Sci 2011, 257:3307–3312.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions SDL participated in the design of the study, carried out the experiments, and performed the statistical analysis, as well as drafted the manuscript. ZZX and CQZ helped in the experiments and data analysis. LM participated in the design of the experimental section and offered help in the experiments. MJZ participated in the design of the study,
provided the theoretical and experimental guidance, performed the statistical analysis, and revised the manuscript. WZS gave his help in using the experimental apparatus. PX-478 manufacturer All authors read and approved the final manuscript.”
“Background Paclitaxel is a chemotherapeutic agent used for the treatment of cancers. It acts by interfering with a cell’s microtubule function by stabilizing microtubule formation, thereby inhibiting mitosis and normal cell division. Paclitaxel shows broad
anti-tumor activity Megestrol Acetate and is used to treat a wide variety of cancers such as ovarian, breast, non-small cell lung, head and neck cancer, and advanced forms of Kaposi’s sarcoma [1–4]. Despite its broad use as a chemotherapeutic, the CFTR inhibitor delivery of paclitaxel is challenging. Paclitaxel is a well-known BCS class IV drug with poor solubility and poor permeability which serves to limit its oral uptake. Also, paclitaxel is a substrate of the membrane-bound drug efflux pump P-glycoprotein (P-gp), which can prevent oral absorption or uptake by mediating direct excretion of the drug into the intestinal lumen [1, 5]. Finally, significant pre-systemic first-pass metabolism in the liver by the cytochrome P450 enzymes further reduces the oral bioavailability of paclitaxel [6–8]. As a result of the described challenges to oral delivery, the current route of paclitaxel administration is via the intravenous (IV) route. Due to its poor solubility, paclitaxel is dissolved in organic mix of Cremophor EL (BASF, Ludwigshafen, Germany):ethanol (1:1 v/v) for intravenous delivery.